Preston Harris Tolbert

Dr. Preston Harris Tolbert

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
John A TreffallsJohn A Treffalls
John A Treffalls
RTRebecca N. Treffalls
Rebecca N. Treffalls
HZHarbin Zachary
Harbin Zachary
WCWesley Clothier
Wesley Clothier
PTPreston Harris Tolbert
Preston Harris Tolbert
MDMark G Davies
Mark G Davies

27 July 2023 in Phlebology: The Journal of Venous Disease
Verified
Journal Article
Closed access
PTPreston Harris Tolbert
Preston Harris Tolbert
JTJohn Treffalls
John Treffalls
WCWesley Clothier
Wesley Clothier
ZHZach Harbin
Zach Harbin
QYQi Yan
Qi Yan
MDMark G Davies
Mark G Davies
Objective: This study seeks to evaluate the quality and readability of freely available online patient information resources for deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods: Internet searches were performed for five DVT and PE search terms in July 2020 across three search engines and two metasearch engines. Qualitative content analysis was performed. Readability was assessed using four validated instruments. Results: Two hundred fifty websites were identified of which 62 websites met inclusion criteria. Website structure and content were satisfactory (>50% overall score), accountability was mixed between DVT (47%) and PE (56%) sites, while interactivity was poor (<30%). On qualitative content analysis, anticoagulation (95.2%) was the most discussed treatment while the most discussed procedures were IVC filter placement for DVT and thrombolysis for PE. Overall readability was difficult with median level suitable for ages 14–18 years. Conclusion: Freely available online DVT and PE patient information resources publish appropriate content but have very variable accountability and poor readability for the average patient.

9 July 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
STSamantha Aguilar Tolbert
Samantha Aguilar Tolbert
Mollie VanNatta DayMollie VanNatta Day
Mollie VanNatta Day
AAAline Arif
Aline Arif
PTPreston Harris Tolbert
Preston Harris Tolbert
DDDestyn Dicharry
Destyn Dicharry
AMAlexandre Malek
Alexandre Malek
Background: Vancomycin-resistant enterococci (VRE) Enterococcus faecalis (E. faecalis) remains largely ampicillin-susceptible, yet broad-spectrum agents are frequently used empirically (i.e., daptomycin and linezolid). Despite its frequent susceptibility to ampicillin, VRE E. faecalis is often managed with broad-spectrum antimicrobials, raising concerns about overtreatment and antimicrobial stewardship. Resistance mechanisms vary, with vancomycin resistance mediated by vanA/vanB operons and beta-lactams by altered penicillin binding proteins. These distinct mechanisms help explain why VRE E. faecalis isolates may remain susceptible to ampicillin, supporting its potential use in clinical isolates. This study aims to describe the antibacterial susceptibility results of Enterococcus faecalis VRE and assess antibiotics use in clinical settings in a tertiary medical center. Methods: This was a single-center, retrospective, descriptive study of hospitalized and outpatient adults with Enterococcus faecalis VRE isolates identified between 1 June 2018 and 15 March 2025. We excluded individuals with concomitant non-Enterococcus faecalis VRE infections and those aged 32 mcg/mL per the 35th edition of the Clinical and Laboratory Standards Institution breakpoints. Results: A total of 337 patients were screened; 114 met inclusion criteria. The cohort was 54% female, 50% Black, and 48% White, with 54% having hypertension, 36% diabetes, and 19% a history of multidrug-resistant organism carriage. The most common source of infection was urinary (67%), followed by skin and soft tissue infections and bone/joint infections (11% each). All isolates were vancomycin-resistant; 82% were susceptible to ampicillin, 84% to nitrofurantoin, 61% to daptomycin, and 70% to linezolid. Antimicrobial regimens varied, with daptomycin being the most used agent (19%). No patients in the aminopenicillin group experienced 30-day mortality, whereas two patients (3%) in the non-aminopenicillin group died within 30 days. Acute kidney injury occurred in four patients (29%) in the aminopenicillin group compared with four patients (7%) in the non-aminopenicillin group, representing a significantly higher incidence in the aminopenicillin group (p = 0.037). However, myalgia, elevated creatine phosphokinase, and thrombocytopenia were more common in the non-aminopenicillin group. Conclusions: Despite higher susceptibility to ampicillin and nitrofurantoin, daptomycin was the most used agent for VRE E. faecalis infections. These findings highlight a need for improved antimicrobial stewardship and further clinical studies to guide optimal therapy.

2 July 2026
Verified
Book Chapter
Closed access
PDF file
GMGauri Mankekar
Gauri Mankekar
PTPreston Harris Tolbert
Preston Harris Tolbert